Analysis of Pharmaceutical Joint Ventures In China
This article was originally published in PharmAsia News
South Medicine Economic Research Institute of China's State FDA recently released an analysis of pharmaceutical joint ventures in the country. These organizations' market shares have been increasing steadily at the expense of local and overseas drug companies, rising from 31.67 percent in 2002 to 40.16 percent in 2006. Several key trends are observed in these collaborative businesses: 1) a move toward full proprietorship; 2) R&D setup in China; 3) a switch from prescription to OTC drugs; 4) localization of drug preparation; and 5) accelerated development of tertiary market. An overview is provided of the top 10 China pharmaceutical joint ventures, namely, Shanghai Roche, Dalian Pfizer, AstraZeneca (Wuxi), Beijing Bayer, Sanofi-Synthélabo Minsheng, Hangzhou MSD, Suzhou Lilly, Beijing Novartis, Shanghai Squibb and Jiangsu Sino-Swed. (Click here for more - Chinese Language)
You may also be interested in...
Guardant’s CEO anticipates accelerated adoption and reimbursement of its FDA-approved liquid biopsy assay and more biopharma partnerships.
Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m.
Agency commissioner appeals to AMA audience to communicate message that FDA review decisions are based on good science.